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Abstract 
Background:  
Cancer-associated fatigue and the chronic adverse effects of cancer therapy can be reduced by 
Lipid  Replacement  Therapy  (LRT)  using  membrane  phospholipid  mixtures  given  as  food 
supplements.  
 
Methods:  
This is a review of the published literature on LRT and its uses. 
 
Results:  LRT significantly reduced fatigue in cancer patients as well as patients suffering from 
chronic fatiguing illnesses and other medical conditions.  It also reduced the adverse effects of 
chemotherapy,  resulting  in  improvements  in  incidence  of  fatigue,  nausea,  diarrhea,  impaired 
taste,  constipation,  insomnia  and  other  quality  of  life  indicators.    In  other  diseases,  such  as 
chronic fatigue syndrome, fibromyalgia syndrome and other chronic fatiguing illnesses, LRT 
reduced fatigue by 35.5-43.1% in different clinical trials and increased mitochondrial function. 
  
Conclusions:  LRT formulations appear to be useful as non-toxic dietary supplements for direct 
use or placed in functional foods to reduce fatigue and restore mitochondrial and other cellular 
membrane functions.  Formulations of LRT phospholipids are suitable for addition to various 
food products for the treatment of a variety of chronic illnesses as well as their application in 
anti-aging and other health supplements and products. Functional Foods in Health and Disease: 4:135-160                                                                          Page 136 of 160 
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Background 
Nutritional  supplements  are  often  taken  to  maintain  health  and  prevent  disease,  but  cancer 
patients routinely take multiple dietary supplements to prevent recurrence of cancer, reduce the 
adverse effects of cancer therapy and to improve quality of life [1-4].  Indeed, one of the most 
common changes in behavior among cancer patients is initiation of the use of multiple dietary 
supplements [3]. 
Studies conducted on the routine use of dietary supplements by cancer patients as well as 
cancer survivors indicate that there is often little consideration as to their safety, efficacy and 
potential negative effects [5, 6].  In fact, some data suggest that higher than recommended doses 
of  some  vitamins  and  minerals  might  result  in  enhancement  of  carcinogenesis,  changes  in 
survival in some cancers and interference with therapy or prescription medications [5, 6].  In 
cancer  patients  several  potentially  beneficial  effects  of  dietary  supplements  have  been 
documented, including reductions in the risk of cancer carcinogenesis and tumor progression, 
enhancement of immune responses against cancer or immune systems in general, improvements 
in nutrition and general health, and reductions in the adverse effects of cancer therapy [3-5, 7-
14].  Here we will focus on one of the most troublesome aspects of cancer and its therapy: 
cancer-associated fatigue. 
 
Introduction 
One of the most common symptoms in cancer that can add considerably to cancer morbidity is 
cancer-associated fatigue [13-16]. It exists in all types of cancers from the least to the most 
progressed cancers [15, 16].  Along with pain and nausea, it is one of the most common and 
troublesome symptoms of cancer  [16, 17].  Cancer-associated fatigue is especially apparent in 
advanced cancers where the systemic adverse effects of cancer therapy are almost always present 
[17-19].   
In  advanced  cancer  patients  receiving  adjuvant  therapies  the  prevalence  of  cancer-
associated fatigue is reported to be as high as 95% [20]. Thus cancer-associated fatigue is a 
problem before, during and after therapy, and it can continue to be a problem years after cancer 
treatment has stopped [16, 19].  Cancer-associated fatigue has a very strong negative effect on 
quality  of  life;  therefore,  addressing  and  reducing  cancer-associated  fatigue  should  be  an 
important consideration in the treatment of cancer [14, 19]. 
   Although not well understood, cancer-associated fatigue is thought to be a combination 
of the effects of having cancer plus the effects of cancer treatments [16, 19].  Unfortunately, 
cancer-associated fatigue is rarely treated, and is often thought to be an unavoidable symptom 
[15,  16].    Cancer-associated  fatigue  can  be  considered  to  be  the  product  of  a  variety  of 
contributing factors [21].   In addition to a decrease in the availability of cellular energy, such as Functional Foods in Health and Disease: 4:135-160                                                                          Page 137 of 160 
 
provided by mitochondria, there exist psychological and medical factors that determine states of 
fatigue. The psychological factors include depression, anxiety, sleep disturbances, among others, 
and the medical factors include anemia, endocrine changes, poor nutritional status and release of 
inflammatory  cytokines  [11-14,  19-23].      All  of  these  factors  can  all  contribute  to  cancer-
associated fatigue [12-14].    
Cancer-associated  fatigue  does  not  occur  as  an  isolated  symptom.    Cancer  patients 
usually  have  a  variety  of  symptoms,  including  cancer-associated  fatigue.    Cancer-associated 
fatigue  occurs  as  one  of  multiple  symptoms  that  are  present  at  all  stages  of  cancer,  with 
exception  of  the  very  earliest  stages.    Cancer-associated  fatigue  is  similar  to  many  other 
symptoms in cancer patients, in that the severity of cancer-associated fatigue usually correlates 
with decreased functional abilities [24].  
Cancer therapy also contributes in an important way to cancer-associated fatigue [19-21].  
In fact, the most commonly found and disabling effect of cancer therapy is fatigue [20, 24, 25]. 
During cancer therapy fatigue problems can vary, from mild to severe, and excess fatigue during 
cancer therapy is an important reason given by patients when they discontinue therapy [26].  
When Manzullo and Escalante  [23] reviewed the literature on the effects of cancer therapy on 
cancer-associated fatigue, they found that 80-96% of patients receiving chemotherapy and 60-
93% receiving radiotherapy experienced moderate to severe fatigue.  Fatigue not only was a 
significant problem during cancer therapy, but it continued for months to years after the therapy 
ended [23].  Thus in cancer patients suppressing cancer-associated fatigue as well as controlling 
therapy-induced fatigue are important in supportive cancer care [27].  
Recent  research  on  cancer-associated  fatigue  has  been  directed  at  understanding  and 
treating cancer-associated fatigue as well as developing ways to distinguish between depression 
and cancer-associated fatigue [15].  Depression is a common complaint of cancer patients.  Both 
cancer-associated  fatigue  and  depression  have  multidimensional  and  heterogeneous  qualities.  
For example, they both possess physical, cognitive and emotional dimensions, and there is a 
certain degree of overlap across these dimensions [15, 20].   
Fatigue or loss of energy is a core symptom in diagnosing depression.  Thus both fatigue 
and depression are often diagnosed together.  This is usually accomplished by self-assessment, 
where  fatigue  and  depression  are  considered  to  be  part  of  a  clinical  symptom  cluster,  co-
morbidity or syndrome [28, 29].  There are procedures, however, that can distinguish between 
cancer-associated fatigue and depression by removal of fatigue-associated assessments from an 
analysis of depression [30, 31].  Criteria have been established when assessing fatigue or cancer-
associated fatigue that take depression into consideration, and these two symptoms can thus be 
separated from one another by considering unshared properties [32]. 
Chronic fatigue lasting more than 6 months that is not reversed by normal sleep is the 
most common complaint of patients seeking general medical care  [33, 34].  Fatigue occurs 
naturally during aging, and it is also an important secondary condition in many clinical diagnoses 
[34, 35].  Most patients understand fatigue as a loss of energy and inability to perform even Functional Foods in Health and Disease: 4:135-160                                                                          Page 138 of 160 
 
simple tasks without exertion.  Many medical conditions are associated with fatigue, including 
respiratory,  coronary,  musculoskeletal,  and  bowel  conditions  as  well  as  infections  [33-35].  
Fatigue is the most common complaint made by the overwhelming majority of cancer patients 
[16, 19-21].  
 
Fatigue and its Relationship to Oxidative Stress and Damage to Mitochondria 
An important phenomenon associated with cancer and its progression as well as aging and age-
related  degenerative  diseases  is  oxidative  stress  [36-39].    Oxidative  stress  is  caused  by  an 
intracellular  excess  of  reactive  oxygen  (ROS)  and  nitrogen  (RNS)  free  radical  species  over 
intracellular  antioxidants.    When  this  imbalance  occurs,  it  results  in  oxidation  of  cellular 
structures, such as membrane lipids and proteins; it also causes mutation of mitochondrial and 
nuclear DNA [39-42].  The free radicals ROS and RNS are naturally occurring cellular oxidants 
that are usually present in low concentrations; they are important cellular regulators and are 
involved in gene expression, intracellular signaling, cell proliferation, antimicrobial defense and 
other normal cellular processes [43-45].  However, when ROS/RNS are in excess over cellular 
antioxidants, oxidative damage can occur to cellular structures [39, 44-46].  Recently Maes [47] 
proposed a link between excess oxidative stress and activation of ROS/RNS pathways, which is 
in turn linked to fatigue and fatiguing illnesses. 
Cellular antioxidant defenses usually maintain ROS/RNS at appropriate concentrations 
that prevent excess oxidation of cellular structures [48-50].  Some of the endogenous cellular 
antioxidant defenses are mediated by glutathione peroxidase, catalase and superoxide dismutase, 
among other enzymes [51, 52].  There are also low molecular weight dietary antioxidants that 
can affect anti-oxidant status [53, 54].  Some of these dietary antioxidants have been used as 
natural chemopreventive agents to shift the excess concentrations of oxidative molecules down 
to more physiological levels [55, 56]. 
Excess  oxidative  stress  and  its  mediators  (ROS/RNS)  within  cancer  cells  have  been 
linked to promotion and progression of cancer malignancy (metastasis) [57-61].  To demonstrate 
this oxidative stress and antioxidant status have been examined in various malignant cancers, 
such as breast [58-62], prostate [63, 64], colorectal [65, 66], renal [67, 68], and other cancers 
[69-71].    In  all  of  these  different  cancers  ROS/RNS  were  in  excess  of  cellular  antioxidant 
concentrations, resulting in excess oxidative stress.  Therefore, these cancers could have been 
induced as a consequence of excess ROS/RNS and oxidative damage to the genetic apparatus 
[37, 39, 72].  Even more likely than carcinogenesis is the progression of tumors that might not 
evolve to malignancy in the absence of excess oxidative stress [11-14]. 
 
Excess Oxidative Stress and Severe Fatigue Caused by Cancer Therapy  
Cancer  therapy,  such  as  chemotherapy,  can  result  in  the  generation  of  excess  ROS/RNS 
[reviewed in 8, 9, 11, 12].   Thus cancer therapy and the resulting production of excess oxidative 
stress can damage biological systems other than tumors [8, 9, 11, 12].  During chemotherapy the Functional Foods in Health and Disease: 4:135-160                                                                          Page 139 of 160 
 
highest known levels of oxidative stress are generated by anthracycline antibiotics, followed in 
no particular order by alkylating agents, platinum-coordination complexes, epipodophyllotoxins, 
and camptothecins [8, 9].  The primary site of ROS/RNS generation during cancer chemotherapy 
is the cytochrome P450 monooxygenase system within liver microsomes.  Enzyme systems, such 
as the xanthine-xanthine oxidase system, and non-enzymatic mechanisms (Fenton and Haber-
Weiss reactions) also play a role in creating excess oxidative stress during chemotherapy [8, 9].  
The very high levels of oxidative stress caused by anthracyclines is also related to their ability to 
displace  coenzyme  Q10  (CoQ10)  from  the  electron  transport  system  of  cardiac  mitochondria, 
resulting in diversion of electrons directly to molecular oxygen with the formation of superoxide 
radicals [reviewed in 8, 9]. 
Anthracyclines  and  other  chemotherapeutic  agents  cause  generation  of  high  levels  of 
ROS/RNS, but not all chemotherapeutic agents generate excess oxidative stress.  Some agents 
generate  only  modest  amounts  of  ROS/RNS.    Examples  of  this  are:  platinum-coordination 
complexes and camptothecins, taxanes, vinca alkaloids, anti-metabolites, such as the anti-folates, 
and nucleoside and nucleotide analogues [8, 9, 11, 12].  However, most chemotherapeutic agents 
generate some oxidative stress, as do all anti-neoplastic agents when they induce apoptosis in 
cancer cells [8, 9].  Drug-induced apoptosis is usually triggered by the release of cytochrome c 
from the mitochondrial electron transport chain.  When this occurs, electrons are diverted from 
NADH dehydrogenase and reduced CoQ10 to oxygen, resulting in the formation of superoxide 
radicals [8, 9, 73]. 
Chemotherapeutic agents used to treat cancer cause oxidative stress, which produces side 
effects, and among the most common side effects is chronic fatigue [8, 9, 11, 12].  Chronic 
fatigue caused by cancer therapy can reduce therapeutic efficacy [12, 13].  Although many anti-
neoplastic agents have clearly established mechanisms of action that are not dependent upon the 
generation of ROS/RNS, these drugs can only mediate their anticancer effects on cancer cells 
that are exhibiting unrestricted progression through the cell cycle. They must also have intact 
apoptotic pathways.  Thus oxidative stress interferes with cell cycle progression by inhibiting the 
transition of cells from the G0 to G1 phase, slowing progression through S phase by inhibition of 
DNA synthesis. This results in inhibition of cell cycle progression of the G1 to S phase, and it 
also results in inhibition by checkpoint arrest [74-78]. 
Chemotherapeutic agents can also activate DNA repair systems. DNA repair of damage 
caused by alkylating agents and platinum complexes results in resistance to these drugs, and 
checkpoint  arrest  during  oxidative  stress  can  enhance  the  repair  processes  and  diminish  the 
efficacy of treatment  [79-81]. Abolishing checkpoint arrest  produces  the opposite effect  and 
enhances the cytotoxicity of anti-neoplastic agents.  By reducing oxidative stress, antioxidants 
counteract the effects of chemotherapy-induced oxidative stress on the cell cycle and enhance the 
cytotoxicity of antineoplastic agents [8, 9]. 
Important intracellular signal transduction pathways that are necessary for the action of 
some antineoplastic agents can also be affected by oxidative stress [8, 9, 82, 83]. There are two Functional Foods in Health and Disease: 4:135-160                                                                          Page 140 of 160 
 
major pathways of drug-induced apoptosis following cellular damage by anti-neoplastic agents: 
(1) The mitochondrial pathway, initiated by release of cytochrome c; and (2) the CD95 death 
receptor pathway, initiated by CD95L binding to its death receptor [8, 9, 81].  Oxidative stress 
during chemotherapy results in the generation of highly electrophilic aldehydes that have the 
ability to bind to the nucleophilic active sites of caspases as well as the extracellular domain of 
the  CD95  death  receptor.    This  inhibits  caspase  activity  and  the  binding  of  CD96L  ligand, 
resulting in impairment of the ability of anti-neoplastic agents to initiate apoptosis [82-84]. 
Similar to chemotherapy, radiotherapy also results in generation of oxidative stress and 
excess ROS/RNS [85, 86].  The principal target of radiation in cancer cells is DNA, and DNA 
can be directly damaged by radiation.  However, genetic damage is also mediated by excess 
ROS/RNS [86, 87].  Recently the principal source of excess ROS/RNS during radiotherapy has 
been  shown  to  be  mitochondrial  [87,  88].    Thus  the  initial  cytotoxicity  of  radiation  is  now 
thought to be due to excess ROS/RNS, which triggers apoptosis via alteration of mitochondrial 
metabolism.    This  causes  transiently  opening  of  mitochondrial  permeability  transition  pores, 
which increases the influx of calcium ions into the mitochondrial matrix. The influx of calcium 
ions stimulates mitochondrial nitric oxide synthase and generation of nitric oxide, which then 
inhibits  the  respiratory  chain  and  eventually  stimulates  excess  ROS/RNS  free  radicals  that 
initiate apoptosis [88, 89]. 
 
Cancer Therapy, its Adverse Side Effects and Damage to Cellular Mitochondria 
Cancer therapy is associated with several adverse side effects.  One of the most difficult side 
effects is caused by chemotherapeutic drug (or radiotherapeutic) damage to mitochondria [8, 9, 
11, 12].  Cardiac mitochondria are especially sensitive to certain chemotherapy agents, such as 
anthracycline antibiotics [8, 9]. Anthracycline-induced cardiac toxicity is characterized by acute, 
reversible  toxicity  that  causes  electrocardiographic  changes  and  depressed  myocardial 
contractility and by chronic, irreversible, dose-related cardiomyopathy [9, 90].  The selective 
anthracycline-induced toxicity to cardiac cells is due to damage to cardiac mitochondria.  The 
sensitivity of cardiac cells to anthracyclines, such as doxorubicin, has been found to be due to the 
unique  properties  of  cardiac  mitochondria,  which  possess  a  Complex  I-associated  NADH 
dehydrogenase in the inner mitochondrial membrane facing the mitochondrial cytosol [91, 92]. 
Small molecules can penetrate the outer mitochondrial membrane; thus doxorubicin as a 
relatively  small  molecule  can  readily  penetrate  the  outer  mitochondrial  membrane  [90,  93]. 
However, because it is hydrophilic and cannot partition into the lipid membrane matrix, it cannot 
penetrate  the  inner  mitochondrial  membrane  [93].    Thus,  it  cannot  participate  in  oxidation-
reduction reactions with the type of inner matrix-facing, electron transport chain dehydrogenases 
found in most types of cells, including most tumor cells [90, 93].  But in heart cells doxorubicin 
can interact with the mitochondrial cytosolic-facing NADH dehydrogenase that is unique to this 
tissue [94, 95].  This interaction produces doxorubicin aglycones, which are highly lipid soluble Functional Foods in Health and Disease: 4:135-160                                                                          Page 141 of 160 
 
and readily penetrate the inner mitochondrial membrane [90, 93].   At this location they can 
displace CoQ10 from the electron transport chain [90, 94].    
The  displacement  of  CoQ10  from  the  electron  transport  chain  during  doxorubicin 
treatment  results  in  decreased  CoQ10  in  cardiac  muscle  [96].    This  occurs  as  the  plasma 
concentration of CoQ10 increases [97].  CoQ10 normally accepts electrons from Complexes I and 
II and transfers them down the electron transport chain, resulting in the formation of water.  
However,  the  presence  of  aglycones  in  the  inner  mitochondrial  membrane  and  inner  matrix 
results in the transfer the electrons directly to molecular oxygen, resulting in the formation of 
superoxide radicals [98]. Thus, doxorubicin generates a high level of oxidative stress in cardiac 
mitochondria, causing acute cardiac toxicity and damage to mitochondrial DNA [90, 95, 99]. 
Cardiac  cells  that  are  damaged  by  anthracyclines  cannot  sustain  their  function,  and 
changes in their structure, mostly disruption of mitochondria, eventually results in apoptosis [90, 
100].    This  produces  cardiac  insufficiency  and  an  inability  to  respond  to  pharmacological 
interventions, resulting ultimately in cardiac failure.  However, if CoQ10 is administered during 
anthracycline chemotherapy, damage to  the heart is  prevented by  decreases  in  anthracycline 
metabolism within cardiac mitochondria and by competing with aglycones for the CoQ10 sites 
within  the  electron  transport  chain  [8,  9,  90].    Thus,  CoQ10  administered  concurrently  with 
anthracyclines can maintain the integrity of cardiac mitochondria and prevent damage to the 
heart, and at the same time enhancing the anti-cancer activity of anthracyclines [8, 9, 90]. 
In addition to chemotherapy, radiotherapy also produces damage to tissues other than 
cancer tissues. Agents that protect tissues against radiation effects have been used to reduce 
unwanted damage [88, 101]. Such radioprotective agents that have been used to decrease the 
adverse  effects  of  radiotherapy  are:  antioxidants,  free  radical  scavengers,  inhibitors  of  nitric 
oxide  synthase  and  anti-inflammatory  and  immunomodulatory  agents  [88,  101].    The  most 
effective of these target mitochondria, such as proteins and peptides that can be transported into 
mitochondria  and  plasmids  or  nucleotide  sequences.    For  example,  agents  that  target  and 
stimulate mitochondrial manganese superoxide dismutase genes can be used as radioprotective 
agents [88]. 
 
Molecular Replacement of Mitochondrial Components During Cancer Therapy  
Replacement  of  CoQ10  during  chemotherapy  dramatically  prevents  development  of 
anthracycline-induced  cardiomyopathy  and  histopathological  changes  in  heart  tissue  [9,  90].  
Administering CoQ10 can also prevent changes in electrocardiograms (EKG) characteristic of 
anthracycline-induced heart damage [102]. In animals the administration of CoQ10 resulted in 
increased  survival,  improvement  in  their  EKG  patterns,  and  reduced  heart  histopathological 
changes [103].  These preclinical data, along with clinical data [discussed in 11, 12, 90] support 
the contention that CoQ10 protects the heart tissue from anthracycline-induced damage. 
During  chemotherapy  with  anthracyclines  in  some  institutions  cancer  patients  have 
received concurrent administration of CoQ10 to prevent both chronic and acute cardiotoxicity  [9, Functional Foods in Health and Disease: 4:135-160                                                                          Page 142 of 160 
 
11,  12,  90].    For  example,  the  importance  of  administering  CoQ10  on  the  development  of 
doxorubicin-induced cardiotoxicity in patients with lung cancer has been studied by Judy et al. 
[104]. Doxorubicin given alone without CoQ10 caused marked impairment of cardiac function 
with a significant increase in heart rate and a substantial decrease in ejection fraction, stroke 
index and cardiac index.  In contrast, doxorubicin administered along with CoQ10, did not cause 
cardiotoxicity, and cardiac function remained unchanged [104]. Other studies have confirmed 
these results and have shown that CoQ10 can reduce the cardiac toxicity of doxorubicin in adults 
[105, 106] and also in children [107, 108].  Thus in preclinical and clinical studies the data 
indicate that CoQ10 protects the heart from the cardiotoxicity of anthracyclines. 
 
Cancer-Associated Fatigue and Other Adverse Effects of Therapy  
The most common complaint of patients undergoing anti-neoplastic therapy is fatigue, but there 
are also other complaints of patients that are undergoing cancer therapy [13, 14].  These include: 
pain, nausea, vomiting, malaise, diarrhea, headaches, rashes and infections [23, 106, 108].  Other 
more  serious  problems  can  also  occur,  such  as  cardiomyopathy,  peripheral  neuropathy, 
hepatotoxicity, pulmonary fibrosis, mucositis and other effects caused by therapy [23, 26, 106, 
108].  In terms of their cancer-associated fatigue, most patients feel that cancer therapy-caused 
fatigue is an untreatable symptom [25].
  Although fatigue is usually the most commonly reported 
adverse  symptom  during  cancer  therapy,  up  until  recently  there  was  little  effort  directed  at 
reducing  fatigue  before,  during  or  after  cancer  therapy  [109].    The  perception  that  cancer-
associated fatigue is an untreatable symptom has changed recently [12, 14]. 
Reducing cancer-associated fatigue and fatigue associated with cancer therapy are now 
considered  important  therapeutic  goals.    Psychological,  physical,  pharmaceutical  and 
nutraceutical methods have been undertaken to reduce fatigue and improve the quality of life of 
cancer patients [14, 23, 111].  Such treatments are based mainly on suppressing fatigue but also 
on controlling co-morbid or related symptoms, such as pain, anemia, cachexia, sleep disorders, 
depression and other symptoms [14, 23, 111-115]. 
Unfortunately, there is no standard protocol related to treating cancer-associated fatigue 
and related symptoms.  In reviewing the types of supportive measures used to control fatigue and 
related  symptoms,  the  data  suggest  that  graded  exercise,  nutritional  support,  treatment  of 
psychological problems (such as depression with certain anti-depressants or psycostimulants), 
treatment of anemia with hematopoetic growth factors and control of insomnia with cognitive 
behavioral  therapy  or  pharmacological  and  nonpharmacological  therapies  all  have  a  role  to 
various degrees in controlling cancer-associated fatigue [110-115].  Some of these approaches, 
such as the use of pharmacological drugs and growth factors, have been systematically meta-
analyzed in 27 studies [116].  In this limited analysis, only a psycostimulant (methylphenidate) 
and  hematopoetic  growth  factors  (erythropoietin  and  darbopeitin)  were  more  effective  than 
placebo treatments.  Other treatments were no better than placebo in the treatment of cancer-
related fatigue 116].  Functional Foods in Health and Disease: 4:135-160                                                                          Page 143 of 160 
 
 
Cancer-Associated Fatigue, Aging and Mitochondrial Membrane Damage  
As discussed above, cancer-associated fatigue has been defined as a multidimensional sensation 
[14, 35, 112, 113, 116].  Most patients understand fatigue as a loss of energy and inability to 
perform even simple tasks  without exertion  [116, 117].  Cancer-associated fatigue has been 
described  as  the  dysregulation  of  several  interrelated  physiological,  biochemical  and 
psychological  systems  [112,  113],  but  at  the  tissue  and  cellular  levels  fatigue  is  related  to 
reductions in the efficiency of cellular energy systems, mainly found in mitochondria [13, 14, 
118].    Damage  to  mitochondrial  components,  mainly  by  ROS/RNS  oxidation  of  membrane 
phospholipids, can impair mitochondrial function, and this can also result in oxidative damage to 
other cellular structures [reviewed 36, 42, 44].  Mitochondrial membranes and DNA are major 
targets of oxidative stress, and with aging ROS/RNS mitochondrial damage can accumulate [80, 
119]. 
During  aging  and  in  certain  medical  conditions  oxidative  damage  to  mitochondrial 
membranes  impairs mitochondrial function  [80, 119, 120].   For example, in  chronic fatigue 
syndrome patients evidence of oxidative damage to DNA and lipids exists [120, 121] as well as 
oxidized blood markers [122] and muscle membrane lipids [123] that are indicative of excess 
oxidative stress [124].  In chronic fatigue syndrome patients also have sustained elevated levels 
of peroxynitrite due to excess nitric oxide, which can result in lipid peroxidation and loss of 
mitochondrial function as well as changes in cytokine levels that exert a positive feedback on 
nitric oxide production, increasing the rate of membrane damage  [126].  
 
Lipid Replacement Therapy of Oxidized Membrane Components and its Effect on Fatigue  
In cancer patients mitochondrial membranes as well as other cellular membranes are especially 
sensitive to oxidative damage by ROS/RNS, which occurs at high rates in cancer [65, 66, 68-71, 
124].    Oxidation  of  membrane  phospholipids  alters  their  structure,  affecting  lipid  fluidity, 
permeability and membrane function [124, 126, 127].  One of the most important events caused 
by ROS/RNS damage is loss of electron transport function, and this appears to be related to 
mitochondrial membrane lipid peroxidation. Membrane oxidation induces permeability changes 
in mitochondria, and this can cause loss of mitochondrial transmembrane potential, an essential 
requirement of oxidative phosphorylation [128, 129]. 
Lipid  Replacement  Therapy  (LRT)  has  been  used  to  reverse  the  accumulation  of 
damaged phospholipids in mitochondria and other cellular membranes by replacing them with 
unoxidized  phospholipids  [13,  14,  130].  LRT  plus  antioxidants  has  been  show  to  reverse 
ROS/RNS damage and increase mitochondrial function in certain fatiguing disorders, such as 
chronic fatigue, chronic fatigue syndrome and fibromyalgia syndrome [118, 131].  LRT has been 
found to be effective in preventing ROS/RNS-associated changes and reversing mitochondrial 
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LRT with unoxidized phospholipids and antioxidant supplements has been effective in 
replacement of damaged cellular and mitochondrial membrane phospholipids and other lipids 
that are essential structural and functional components of biological membranes [reviewed in 14, 
131].  NTFactor®, a LRT oral supplement containing phospholipids, phosphoglycolipids and 
other membrane lipids, has been used successfully in animal and clinical LRT studies [13, 14, 
118, 131, 132].  NTFactor's encapsulated lipids are protected from oxidation in the gut and can 
be absorbed and transported into tissues via lipid carriers without oxidation.  Once inside cells 
the membrane lipids naturally replace oxidized, damaged membrane lipids by natural diffusion, 
and carrier proteins pick up the damaged lipids for degradation, transport and excretion [134]. 
In preclinical studies NTFactor® lipids have been used to reduce age-related functional 
damage, such as hearing loss associated with aging in rodents.  NT Factor® lipids prevented 
hearing loss associated with aging and shifted the threshold hearing from 35-40 dB in control, 
aged rodents to 13-17 dB [134].  They also found that NT Factor® lipids preserved cochlear 
mitochondrial function and prevented aging-related mitochondrial DNA deletions found in the 
cochlear [134]. Thus NT Factor® lipids were successful in preventing age-associated hearing 
loss and reducing mitochondrial damage and DNA deletions in rodents [134]. 
In  clinical  studies  LRT  has  been  used  to  reduce  fatigue  and  protect  cellular  and 
mitochondrial membranes from oxidative damage by ROS/RNS [reviewed in 13, 14, 131].  A 
LRT-vitamin mixture containing NT Factor®  (Propax
TM with  NT Factor®) was by used by 
Ellithorpe et al. [132] in a study of patients with severe chronic fatigue and was found to reduce 
their fatigue by approximately 40.5% in 8 weeks.  In these studies fatigue was monitored by use 
of the Piper Fatigue Scale to measure clinical fatigue and quality of life [135].  In a subsequent 
study we examined the effects of NT Factor® on fatigue and mitochondrial function in patients 
with moderate to severe chronic fatigue [118].  Oral administration of NT Factor® for 12 weeks 
resulted in a 35.5% reduction in fatigue and 26.8% increase in mitochondrial function; whereas 
after a 12-week wash-out period fatigue increased and mitochondrial function decreased back 
towards control levels [118].  Thus in fatigued subjects dietary LRT can significantly improve 
and even restore mitochondrial function and significantly decrease fatigue.  Similar findings 
were observed in chronic fatigue syndrome and fibromyalgia syndrome patients [131].  Recently 
a new formulation of NT Factor® plus vitamins, minerals and other supplements (Revacel
TM 
with NT Factor®) resulted in a 36.8% reduction in fatigue within one week [136] (Table 1). 
 
Lipid Replacement Therapy in Conjunction with Cancer Therapy 
LRT has been used to reduce the adverse effects of chemotherapy in cancer patients [reviewed in 
14].  For example, a vitamin-mineral mixture with NTFactor (Propax
TM with NTFactor®) has 
been used in cancer patients to reduce some of most common adverse effects of cancer therapy, 
such as chemotherapy-induced fatigue, nausea, vomiting, malaise, diarrhea, headaches and other 
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cancers  receiving  a  12-week  chemotherapy  treatment  schedule  of  5-florouracil/ 
methotrexate/leukovorin LRT was used to reduce adverse effects of chemotherapy [137].   
 
Table 1.  Effects of dietary LRT supplement NTFactor on Piper Fatigue Scale scores.
1 
 
______________________________________________________________________________ 
           Av      Time    Piper Fatigue Scale 
Subjects/patients    n   age  on LRT  fatigue reduction (%)  Reference 
______________________________________________________________________________ 
 
Chronic fatigue
2    34  50.3    8 wks   40.5**             Ellithorpe et al. [132] 
 
Aging, chronic fatigue
3  20  68.9  12 wks   35.5*           Agadjanyan et al. [118] 
   
Chronic fatigue syndrome  
(and/or fibromyalgia  
syndrome
#)
2      15  44.8    8 wks   43.1*    Nicolson & Ellithorpe [131] 
 
Obesity, fatigue
4    35  42   8 wks   24*              Nicolson et al. [138] 
 
Aging, chronic fatigue
5  67  57.3    1 wk    36.8*      Nicolson et al. [136]  
______________________________________________________________________________ 
 
1Modified from Nicolson [14] 
2Propax
TM with NT Factor® 
3NT Factor® 
4Healthy Curb
TM with NT Factor® 
5Advanced Physician’s Formula
TM or Revacel
TM with NT Factor® 
**P<0.0001,  *P<0.001 compared to without NT Factor® 
#5/15 fibromyalgia syndrome; 3/15 chronic fatigue syndrome plus fibromyalgia syndrome 
______________________________________________________________________________ 
 
In the first unblinded part of the clinical study the effectiveness of NTFactor in a vitamin-mineral 
mixture  (Propax
TM  with  NTFactor®)  administered  before  and  during  chemotherapy  was 
determined by examining signs and symptoms, and in particular, the side effects of therapy.   A 
quality of life evaluation was conducted by a research nurse, and it was determined that patients 
on  NTFactor  supplementation  experienced  significantly  fewer  episodes  of  fatigue,  nausea, 
diarrhea, constipation, skin changes, insomnia and other side effects [137]. In this open label trial 
81% of patients demonstrated an overall improvement in quality of life parameters while on 
chemotherapy  with  LRT  [137].    In  the  double-blinded,  cross-over,  placebo-controlled, 
randomized  part  of  the  study  on  advanced  cancers  the  patients  on  chemotherapy  plus  LRT 
showed improvements in signs/symptoms associated with the adverse effects of chemotherapy 
[137].  Adding  LRT resulted in  improvements  in  the incidence of  fatigue, nausea, diarrhea, 
impaired taste, constipation, insomnia and other quality of life indicators.  Following cross-over 
from  the  placebo  arm  to  the  LRT  arm,  57-70%  of  patients  on  chemotherapy  reported 
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indicators [137] (Table 2). This clinical trial and other data clearly demonstrated the usefulness 
of LRT given during chemotherapy to reduce the adverse effects of cancer therapy [reviewed in 
14].  
 
Table 2.  Effects of LRT (Propax
TM with NTFactor®) on the adverse effects of cancer 
chemotherapy in a cross-over clinical trial.
1,2 
______________________________________________________________________________ 
               Average % patients on test arm
3_________ 
First arm      Second arm    improvement        no change       worsening 
______________________________________________________________________________ 
placebo      Propax
TM+NT Factor®  57       22       21 
Propax
TM+NT Factor®  placebo      70        6       24 
______________________________________________________________________________ 
1Table modified from Nicolson [14]. 
2The same regimen of 5-flurouracil/methotrexate/leukovoran was used for colon, pancreatic or rectal cancers. 
3The percent of patients’ self-reporting adverse effects was averaged with the percent of patients with adverse 
effects reported by a research nurse. 
______________________________________________________________________________ 
 
 
Potential New Lipid Replacement Therapy Products and their Possible Uses 
In addition to use of LRT in cancer patients before, during and after their anti-cancer therapy, 
LRT has a number of other uses in many possible new products.  Some of the possible new 
products  containing  LRT  formulations  are  listed  in  Tables  3  and  4.    For  example,  LRT 
formulations could have a variety of new uses as additives to functional foods (Table 3) or as 
condition-specific dietary supplements (Table 4).  Some existing uses of LRT formulations in 
conditions other than cancer are as follows. 
 
Table 3.  Potential Functional Food products where LRT can be added. 
____________________________________________________________________________ 
Nutritional Products    Beverages    Dairy Products  Energy Foods 
____________________________________________________________________________ 
 
Fruit powders     Energy drinks   Yogurts  `  Energy bars 
Vegetable powders    Fruit drinks    Milk      Energy drinks 
Protein powders    Vegetable drinks  Cheeses    Energy shots 
Meal replacements    Soy milk    Sour cream    Antioxidant drinks 
Cereals      Vitamin drinks  Cottage cheese  Cookies 
Frozen foods      Probiotic drinks  Butter      Energy chews 
Breads and bakery goods  Milk      Ice cream    Powders 
Soups              Soy ice cream 
Pet foods             
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Table 4.  Potential condition-specific dietary supplements with added LRT. 
__________________________________________________________________________ 
 
Amino acid supplements        Herbal supplements 
Anti-aging supplements        Hormone supplements 
Bone and joint supplements        Liver health supplements 
Brain health supplements        Urinary health supplements 
Cellular support supplements       Mood relief supplements 
Digestive support supplements      Prostate health supplements 
Heart health supplements        Sports performance supplements 
Fiber supplements          Weight loss supplements 
Immune enhancement supplements      Multivitamin supplements 
Inflammatory support supplements      Essential fatty acid supplements 
       
___________________________________________________________________________ 
 
LRT and Weight Loss 
Many individuals have weight issues or are obese, and weight reduction regimens that use drugs 
or stimulants can result in increased fatigue.
  We have studied the use of LRT in a weight loss 
clinical trial using a NT Factor® mixture with an FDA-approved amaylase inhibitor (Healthy 
Curb
TM) [138]. The objective was to see if subjects could safely lose weight without increasing 
appetite or fatigue and without changing eating or exercise patterns or using drugs, herbs or 
caffeine. A 2-month open label clinical trial with Healthy Curb
TM was initiated.  Weight and 
measurements were taken weekly, appetite was assessed and fatigue was determined using the 
Piper Fatigue Scale [135].  We found that sixty-three percent of the participants lost an average 
of 6 pounds along with 2.5 and 1.5 inch reductions in waist and hip circumference, respectively, 
and the entire group of participants lost an average of 3 pounds with average reductions of 1.5 
and 1 inch waist and hip  circumference, respectively.   Participants  experienced  gradual and 
consistent weight loss along with reductions in waist and hip measurements, body mass index 
(BMI) and basal metabolic rate (BMR) during the entire trial [138].  There was a 44% reduction 
in  overall  hunger  with  reduced  cravings  for  sweets,  and  thus  notable  appetite  suppression 
occurred during the trial.  The entire test group showed an average of 24% decrease in overall 
fatigue.  Blood lipid profiles generally improved, suggesting improved cardiovascular health, and 
no adverse effects were noted clinically or found in blood chemistries [138]. 
 
LRT and Fatiguing Illnesses 
Fatiguing illnesses, such as chronic fatigue syndrome, fibromyalgia syndrome, Gulf War illness 
and other fatiguing illnesses can be successfully treated with LRT, such as NT Factor® and 
products  containing  NT  Factor®  (Table  1).    In  fatiguing  illness  patients  use  of  products 
containing NT Factor® resulted in reductions in fatigue of approximately 35-43% (Table 1) 
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resulted  in  enhanced  qualify  of  life  and  better  mood,  concentration,  cognition  and  other 
symptoms [131, 132, 136], along with enhanced mitochondrial function [118]. 
 
LRT and Anti-Aging Products 
LRT has the potential to reduce the effects of aging.  In animal studies LRT reduced hearing loss 
and DNA mutations associated with aging [135].  In clinical trials using aged subjects (average 
age 68.9) LRT with NT Factor® significantly reduced fatigue by 35.5% in 12 weeks [118].  
When mitochondrial function was  assessed in  these subjects,  there was a 26.8% increase in 
mitochondrial function after LRT with NT Factor® to the levels found in much younger adults.  
After a 12-week wash-out period, fatigue increased and mitochondrial function decreased back 
towards control levels [118].  This indicated that LRT was effective in reversing some of the 
effects of aging, such as fatigue and loss of mitochondrial function.  Anti-aging formulations, 
such  as  Healthy  Aging
TM  with  NT  Factor®,  have  been  used  to  repair  damaged  cellular 
membranes and reverse some of the other natural oxidative effects of aging. 
 
LRT and Degenerative Diseases 
Patients with neurodegenerative, neurobehavioral and metabolic illnesses all have problems with 
excess  oxidation  damage.  For  example, in  the case of neurological  diseases  brain  cells  are 
particularly vulnerable to oxidative stress and damage caused by excess ROS/RNS.  This is 
because of the brain’s inability to withstand excess oxidative stress due to a high content of 
easily  oxidized  substrates  (membrane  phospholipids),  relatively  low  levels  of  endogenous 
antioxidants,  relatively  high  levels  of  endogenous  generation  of  ROS  and  the  endogenous 
generation of nitric oxide [139-141].  Antioxidant nutraceuticals (natural supplements, vitamins 
and minerals) have been proposed as a strategy to attenuate oxidative damage in neurological 
diseases [142].  In addition, LRT formulations, such as Healthy Aging
TM with NT Factor®, 
contain  a  key  brain  phospholipid  (phosphatidylserine)  that  improves  brain  ―age-associated 
memory  impairment,‖  learning  and  cognitive  performance  that  are  impaired  in  dementing 
disorders like Alzheimer’s disease [143].  LRT could also be used to repair oxidatively damaged 
brain structures, such as mitochondrial and cellular membranes, and reduce the damage caused 
by endogenous oxidation. 
 
LRT and Respiratory Diseases 
Asthma,  chronic  obstructive  pulmonary  disease  and  other  respiratory  conditions  are 
characterized by inflammation and oxidative stress [144, 145].  Antioxidants have been proposed 
to  attenuate the incidence and severity  of  respiratory  attacks  [145].  New products,  such  as 
Breathe  Clear
TM  with  NT  Factor®,  have  been  used  to  reduce  the  symptoms  of  allergic  and 
respiratory inflammation.  In addition to NT Factor®, Breathe Clear
TM contains quercetin and 
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reactions. Quercetin is a flavonol that helps modulate the release of histamine by mast cells 
[146]. 
 
LRT and Cardiovascular Diseases 
Mitochondrial oxidative stress has been implicated, along with other factors, in cardiovascular 
disease  and  heart  attack  [147,  148].    Aging  is  accompanied  by  accumulation  of  cardiac 
mitochondrial  membrane  oxidation,  increased  mitochondrial  DNA  mutations  as  well  as 
decreased production of critical cardiac proteins [147].  Vitamins, minerals, antioxidants and 
other supplements have been suggested as dietary approaches to reduce the risk of myocardial 
infarction  and  coronary  disease  [149,  150].    LRT  could  play  an  important  role  in  repairing 
cardiac mitochondrial and cellular membranes, an important role in cardiovascular health. 
 
LRT, Metabolic Syndrome (Pre-Diabetes) and Type 2 Diabetes 
One of the central defects in metabolic syndrome (a pre-diabetes, pre-cardiovascular disease 
syndrome) and its associated diseases (type-2 diabetes, vascular inflammation, atherosclerosis, 
among other diseases) is excess cellular oxidative stress [151, 152].  Nutritional supplements, 
vitamins, minerals, antioxidants and other supplements [151] as well as LRT with NT Factor are 
important  new  approaches,  along  with  diet,  weight  management  and  lifestyle  changes,  for 
treating metabolic syndrome and preventing its associated diseases [151, 152]. 
 
Conclusions 
Nutritional  supplements  have  been  used  in  a  variety  of  diseases  to  provide  patients  with  a 
natural,  safe alternative  to  pharmacological  drugs.  In patients  with  cancer and other chronic 
illnesses nutritional supplements are often used for specific purposes or to improve quality of 
life.  For example, cancer-associated fatigue is one of the most common symptoms in all forms 
and stages of cancer, but few patients receive assistance for their fatigue.  Cancer-associated 
fatigue  is  associated  with  cellular  oxidative  stress,  and  during  cancer  therapy  excess  drug-
induced  oxidative  stress  can  cause  a  number  of  adverse  effects,  including:  fatigue,  nausea, 
vomiting and more serious effects.  Cancer-associated fatigue and the adverse effects of cancer 
therapy can be reduced with LRT using natural phospholipid supplements that replace damaged 
membrane lipids  along  with  providing  antioxidants  and  enzymatic cofactors.   Administering 
dietary LRT supplements can reduce oxidative membrane damage and restore mitochondrial and 
other cellular functions.  Recent clinical trials using cancer and non-cancer patients with chronic 
fatigue have shown the benefits of specific LRT nutritional lipid supplements in reducing fatigue 
and restoring mitochondrial function.  Newer formulations of LRT supplements will prove to be 
important additions in the treatment of a variety of chronic illnesses as well as useful additions to 
anti-aging and other health products. 
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